This CME-certified prIME News webcast provides is an in-depth review of recent advances in the use of immunotherapy for the treatment of patients with lung cancer.
1.0 AMA PRA Category 1 Credit™
Sep 5, 2017
Sep 5, 2018
A Practical Application of Immunotherapy in Lung Cancer
David Spigel, MD
David Spigel, MDSarah Cannon Research Institute
Nashville, Tennessee, United States
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer.
After completion of this educational activity, participants should be able to:
- Identify recent and emerging efficacy and safety data for immunotherapeutic strategies for the treatment of non-small cell lung cancer (NSCLC)
- Explain the important features of patient selection for immunotherapies
- Identify strategies to recognize and manage adverse events due to the use of immunotherapies
This educational activity is supported by a grant from Merck and Co, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Spigel has disclosed that he has received consulting fees on behalf of his institution from Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Lilly, Novartis, and Pfizer. He also disclosed receipt of research funding to his institution from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Genentech/Roche, Lilly, Merck, Novartis, Oncogenex, OncoMed, Peregrine Pharmaceuticals, Pfizer, and Verastem. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.